Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers

Partnering Platform Now Open for Registration

SAN FRANCISCO — December 12, 2025 — Biotech Showcase™ returns to San Francisco during J.P. Morgan Healthcare Week, marking its 19^th year as a premier destination for global biopharma leaders to showcase their companies and technologies, build relationships, and make deals with venture investors and partners. Taking place January 12-14 and virtually January 21-22, the event will gather more than 1,200 life sciences investors and 3,200 global biopharma professionals, including representatives from companies including PhRMA, BIO, Novo, Ipsen, Regeneron, and Sofinnova Investments.

Attendees can participate in one-to-one meetings with investors, partners and news media, provide corporate presentations, and engage in multiple face-to-face networking sessions. This year’s event will again seamlessly integrate with the TechBio and Seed Showcases, offering unmatched opportunities for investors and partners to engage with companies across the full spectrum of life science innovation. Virtual attendees will benefit from partnering privileges in addition to on-demand access to company showcases and session recordings. Access to extensive on-demand programming, including recordings of sessions and workshops is provided to all attendees.

“Reflecting the significant uptick in M&A and funding across the life sciences ecosystem, Biotech Showcase is set to deliver a record-breaking year in terms of networking and deal-making opportunities,” said Sara Jane Demy, Founder and CEO of Demy-Colton. “This year we’re anticipating more than 300 presenting companies, 1,200 investors and a projected 6,000+ one-to-one meetings, making Biotech Showcase the largest and most influential investor conference for private, micro-cap and mid-cap biotechnology companies, as well as TechBio companies, venture investors, and partnering companies.”

The 2026 agenda will feature discussions on trending topics, including:

• Strategic Adaptation to the New Policy Landscape
• Opportunities in Asia & Europe
• The Pharma Perspective
• The Future of Healthcare Access & Equity
• The Outlook for Biopharma Financing
• AI & Quantum Computing in Healthcare
• Investment in Women’s Health

“With a robust agenda focused on key industry trends in biopharma, and a lineup of exceptional company presentations from both public and private companies, Biotech Showcase has proven itself as the leading platform for connecting innovators and investors across the global biotech community,” Tina Elder, Global Managing Director, EBD Group US, added. “Many thanks to all our investors, speakers, sponsors, media and other attendees for enabling these important conversations that help drive the industry’s funding, collaboration and therapeutic breakthroughs.”

To register for Biotech Showcase or to apply to present or sponsor, please visit https://informaconnect.com/biotech-showcase/.

About Demy-Colton

Demy-Colton is a leading life sciences and digital health events organization at the forefront of building networks between innovative life sciences companies and industry stakeholders. Its unique events facilitate networking on a global scale, including Biotech Showcase™, BioFuture™, Global Biotech CEO Summit™, Executive Clinics™, and Demy-Colton Virtual Salons™. These events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industry’s top decision-makers, investors and thought leaders. For more information, visit www.demy-colton.com. 

About Life Sciences Partnering and Investment by Informa

Our mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe®, BIO-Europe Spring®, Biotech Showcase™, ChinaBio® Partnering Forum, Asia Bio Partnering Forum, BioEquity Europe, LSX USA Congress, Investival Showcase Europe, European Lifestars Awards, Investival Showcase USA, LSX Europe Congress, LSX Nordic Congress) annually attract more than 14,000 senior life science executives who engage in over 83,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

Contacts

Katie Morris, PhD
ENTENTE Network of Companies
katiemorris@ententeinc.com

MC Services, Inc.
Laurie Doyle
Phone: +1-339-832-0752
E-mail: EBDGroup@mc-services.eu

Media release

PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies

Baar, 12 December 2025 – PolyPeptide Group AG (SIX: PPGN), a global CDMO for peptide-based APIs, and Lupin Manufacturing Solutions Limited (LMS) have formed a strategic alliance to enhance supply chain resilience, improve operational efficiency, and support the long-term growth of both organizations.

Through this alliance, PolyPeptide will broaden its sourcing options for key materials, establishing a more robust and flexible supply chain for peptide manufacturing. The agreement sets a framework for long-term cooperation, including integrated procurement and supply planning for select raw materials. Both companies are committed to maintaining high standards of quality, reliability, and compliance.

“Reliability is a competitive advantage in our industry. Working with Lupin Manufacturing Solutions gives us the flexibility and supply chain depth needed to support growing customer demand, including metabolics demand,” said Dr. Stéphane Varray, Chief Commercial Officer, PolyPeptide. “When you’re enabling life-changing therapies, your supply chain must operate as a true strategic capability.”

Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, said, “We are delighted to announce our strategic alliance with PolyPeptide. As peptide-based therapies continue to transform the treatment landscape for metabolic and other chronic conditions, LMS is committed to ensuring reliable access to specialised materials that support large-scale commercial production. This underscores our mission to establish secure, agile, and future-ready supply pathways for innovators worldwide.”

Contact

PolyPeptide Group AG      
Corporate Communications  
Lauren Starr     
mediateam@polypeptide.com    
T: +41 43 502 0580    

PolyPeptide Group AG
Investor Relations
Tim Brandl 
investorrelations@polypeptide.com 
T: +41 43 502 0580 
 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.

For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

About Lupin Manufacturing Solutions Limited (LMS)

Lupin Manufacturing Solutions Limited, a 100% subsidiary of Lupin Limited, is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and a global Contract Development and Manufacturing Organization (CDMO) offering standalone & integrated solutions across drug substances, complex chemistry, drug product, and advanced modalities, including ADCs and peptides. Leveraging Lupin’s legacy of scientific rigor and regulatory expertise, LMS supports biopharma innovators from early development to commercial scale. With state-of-the-art facilities, a client-first approach, and a team of 250+ scientists, LMS accelerates the path to market for transformative therapies.

For more details, visit https://www.lupin.com/LMS/  or email at lmsinfo@lupin.com

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Expansion of the Management Board of M1 Kliniken AG

Berlin, 11. December 2025 – The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025. Ms. Zimmnau has been CFO of M1 Kliniken AG since June 1, 2025.

“I am very pleased to welcome Ms. Zimmnau to the team. With her many years of experience in accounting, controlling, and process design, she will play a key role in shaping the further development of our profitable growth trajectory”, says Attila Strauss, CEO of M1 Kliniken AG.

About M1 Kliniken AG

M1 Kliniken AG is the leading fully integrated provider of medical aesthetic services in Europe and Australia. With a clear strategic focus, high standardization, and consistent scalability, the Group currently operates 58 clinics in ten countries under the M1 Med Beauty brand. All treatments are performed exclusively by qualified physicians and adhere to uniform, high medical standards, while being offered at market-leading prices. Since late 2018, M1 has systematically driven its international expansion, which forms the basis for scalable future growth and the further development of its global market position. With the M1 Schlossklinik in Berlin, the Group operates one of Europe’s largest and most modern clinics for plastic and aesthetic surgery, featuring four operating theaters and 35 beds.

Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de

SCHOTT Pharma delivers on full-year revenue and profitability targets

• Revenue of EUR 986.2m reflects a 5.8% growth at constant currencies
• EBITDA margin at constant currencies increased to 28.4% (prior year: 26.9%)
• Successful expansion of high-value solutions (HVS) – revenue share increased to 57% (prior year: 55%)
• Guidance for FY 2026: 2-5% revenue growth at constant currencies and EBITDA margin of around 27%

SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has successfully concluded its fiscal year 2025¹.Revenue rose to EUR 986.2m, representing an increase of 5.8% at constant currencies (reported +3.0%). Full-year EBITDA grew even stronger and amounted to EUR 280.3m, up 11.5% at constant currencies (reported +8.8%). The corresponding EBITDA margin was 28.4% (reported 28.4%).

“Amid the challenging macroeconomic environment, SCHOTT Pharma once again delivered excellent results, and we met our targets for both revenue and profitability. While our core solutions remain a very solid and profitable business, we have effectively continued to focus on increasing the revenue share of our high-value solutions through product innovation, capacity expansions, and strong partnerships,” said SCHOTT Pharma’s CEO Andreas Reisse. “As we expect the market to remain difficult, we target a revenue growth of 2-5% for fiscal year 2026 and an EBITDA margin of around 27%. This represents a bridge year, as we anticipate market dynamics to pick up again going forward. We update our mid-term guidance and now project a revenue CAGR of 6-8% and an incremental increase of our EBITDA margin over the coming years.”

Reinhard Mayer, CFO of SCHOTT Pharma, adds: “The disciplined execution of our strategy in 2025 has further strengthened SCHOTT Pharma’s financial foundation and bolstered our resilience against the backdrop of geopolitical uncertainties. Over the last six years, we have invested around EUR 800m in our global manufacturing network, particularly for high-value solutions. At the same time, we have further improved our efficiency through automation and digitization, which is also reflected in the positive development of our EBITDA margin. Looking ahead, we remain committed to investing in innovation, capacity and operational excellence to drive sustainable, profitable growth alongside our mid-term expectations.”

Profitable growth driven by high-value solutions

SCHOTT Pharma’s positive development was driven by the Drug Containment Solutions segment (DCS), where revenue increased 11.9% at constant currencies (reported +5.6%) to EUR 548.0m. High-value solution products like sterile ready-to-use cartridges and vials as well as specialty vials for innovative biologic drugs performed particularly well. As a consequence, the segment’s HVS revenue share grew by 6pp to 23%. EBITDA in the DCS segment rose to EUR 127.5m, marking a significant surge of 34.9% at constant currencies (reported +26.0%) due to a favorable product mix and efficiency gains. The corresponding margin went up by 4.0pp to 23.5% (reported 23.3%).

Revenue in the Drug Delivery Systems (DDS) segment were at EUR 438.8m, representing a slight decline of 1.3% at constant currencies (reported: 0.0%). The lower demand for polymer syringes was offset by the sustained high demand for prefillable glass syringes. EBITDA decreased by 9.9% at constant currencies (reported -8.2%) to EUR 152.8m, mainly due to lower utilization as well as ramp-up costs for the new prefillable glass syringe manufacturing facility in Hungary. The segment´s EBITDA margin was at 34.6% at constant currencies (reported 34.8%), down 3.3pp on the previous year’s figure.

Solid cash generation and high growth investments

SCHOTT Pharma’s operating cash flow came in at EUR 179.9m in the reporting year, after EUR 224.8m in 2024. This was mainly due to a higher working capital need and timing of tax payments, which more than offset the EBITDA improvement. At EUR 144.8m, CAPEX was on par with the previous year’s level, as the company continued to invest in capacity expansion, particularly for high-value solutions.

Earnings per share for the reporting year were EUR 0.97 (prior year: EUR 0.99). The Management Board and Supervisory Board will propose a dividend of EUR 0.18 per share for FY 2025 at the Annual General Meeting on February 3, 2026. That would result in a payout ratio of 18% of the profit for the period.

Addressing market needs, preparing for future growth

In fiscal year 2025, SCHOTT Pharma launched several product innovations addressing major market trends, such as the increasing demand for solutions that enable the safe and easy self-administration of injectable drugs at home; the growing and increasingly diverse range of sensitive biologics; as well as the need for a more sustainable manufacturing and reliable supply of drugs and vaccines. The portfolio additions include sterile large-volume syringes and cartridges made of glass and polymer, which further strengthen the company’s product range of high-value solutions.

At the same time, SCHOTT Pharma continued to execute its multi-year expansion plan and achieved important milestones. The company opened a new production site in Serbia and celebrated the groundbreaking for a new facility for sterile ready-to-use cartridges in Hungary.

Outlook

SCHOTT Pharma expects revenue growth at constant currencies of 2-5% for fiscal year 2026 and the EBITDA margin to be around 27%. The sales growth will be entirely driven by the DCS segment. At the same time, the DDS segment will be impacted by the unexpected revised market outlook of a key customer resulting in lower glass syringes demand. Product mix effects and a temporary underutilization of capacities in DDS, as well as ramp-up costs for new factories in Serbia and Hungary is impacting the EBITDA margin in 2026.

Based on this, SCHOTT Pharma updates its mid-term outlook for 2027 to 2029 to a revenue CAGR of 6-8% and expects the EBITDA margin to improve over the coming years towards 30%.

New CEO appointed

On November 5, 2025, SCHOTT Pharma announced that Christian Mias will succeed Andreas Reisse as CEO, effective May 1, 2026. Mias has 20 years of management experience, thereof more than 18 years within the SCHOTT group. There, he has held leadership positions across various business units and continents, in which he drove profitable growth by optimizing processes, improving productivity, and increasing earnings quality. His career also included roles at SCHOTT Tubing, which manufactures glass tubing for the pharmaceutical sector, including for SCHOTT Pharma, where he gained significant experience in the pharmaceutical industry.

For additional news about SCHOTT Pharma, please visit our media center.

Key figures FY 2025

Key figures Q4 2025

Differences in the total numbers in the tables may be due to rounding, and differences in group revenue may result from consolidation and reconciliation effects. / nm = not meaningful

¹The fiscal year runs from October to September. Q4 2025 therefore relates to the period from July 2025 to September 2025.
²cc = at constant currencies

Webcast

CEO Andreas Reisse and CFO Reinhard Mayer will speak at an analyst and investor conference call at 11:00 a.m. CET on 11 December 2025 to discuss the Q4 and FY 2025 results. The audio webcast can be followed via the following link. The accompanying presentation is available on the IR website: www.schott-pharma.com/investor-relations

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Further information at www.schott-pharma.com

Press contact

Lea Kaiser

PR & Communications Manager

Tel.: +49 (0) 151 68917195

E-Mail : lea.kaiser@schott.com

Katrin Schreyer

Global Communications Manager

Tel.: +49 (0) 171 116 7544

E-Mail : katrin.schreyer@schott.com

Investor Relations contact

Tobias Erfurth

Head of Investor Relations

Jasko Terzic

Senior Manager Investor Relations

E-Mail: ir.pharma@schott.com

Presse Release // December 09, 2025

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda^® (Pembrolizumab), in the U.S. and Canada 

• Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206
• Strong early partnering interest underscores industry confidence in Formycon’s biosimilar expertise and development excellence
• Agreement structure includes in total mid-teens-million-euro upfront and 2025 milestone payments, alongside additional development and regulatory milestones and a mid-double-digit-gross-profit-share upon launch
• Clinical development phase of FYB206 nearly completed; primary endpoint data expected in the first quarter of 2026

Planegg-Martinsried, Germany; Ahmedabad, India – Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today jointly announced that they have entered into a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda^®1 (Pembrolizumab), in the U.S. and Canada.

Under the terms of this agreement, Formycon AG will finalize development, prepare and file the regulatory dossier, and supply the product, while Zydus will be responsible for the commercialization of FYB206 in the U.S. and Canada. Meanwhile, FYB206 is approaching the end of its clinical development phase, with primary endpoint data expected in the first quarter of 2026. Following completion of the data package, Formycon will prepare the dossier and submit the biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) in due course.

Dr. Stefan Glombitza, CEO of Formycon, commented: “Partnering with Zydus for the U.S. and Canada marks an important milestone for us. Zydus is an established, high-revenue player with a compelling and forward-looking oncology strategy. It has a strong commercial footprint in the U.S., where it generates nearly half of its global revenue and maintains a robust, scalable presence across key commercial channels. By commercializing over 225 FDA-approved products, including injectables and hospital-use medicines, Zydus has shown solid execution strength in complex launches, supporting the high-quality implementation of FYB206. With a streamlined clinical development program, Formycon has secured a leading role among the developers of a pembrolizumab biosimilar and Zydus´ decision to join forces with us underscores their strong confidence in our expertise in developing complex biosimilar medicines for highly regulated countries. Continuing our indicated partnering approach, we are teaming up with strong local partners at attractive commercial terms as we work together to deliver meaningful value for patients and healthcare systems.”

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, stated: “We are happy to collaborate with Formycon to develop and commercialize a biosimilar of Keytruda^® across U.S. and Canada. This venture marks Zydus’ entry into the North American biosimilar market, debuting with an immunotherapy product. This collaboration also complements Zydus’ recent proposed acquisition of Agenus Inc.’s California, USA based manufacturing facilities, which we plan to integrate and leverage for manufacturing in the future. By combining our expertise and resources, we aim to drive significant organizational growth and deliver maximum value to patients through expanded access to affordable oncology care.”

Upon signature of the agreement, Formycon will be eligible to receive mid-teens-million-euro upfront and milestone payments in 2025. In addition, Formycon will be eligible for further payments linked to the achievement of defined development and regulatory milestones, which in total are expected to amount to a mid–double-digit-million-euro range. Upon market launch, Formycon will obtain a mid–double-digit-share of the gross profits generated in the territory.

Pembrolizumab is a humanized monoclonal antibody that belongs to the group of immune checkpoint inhibitors and is used to treat a variety of tumors. With its broad range of indications in oncology and global sales of US$ 29.5 billion in 2024², Keytruda^® is currently one of the world’s best-selling drugs, underscoring the substantial oncology demand and market potential across the world.

1) Keytruda^® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, (NYSE: MRK) Rahway, NJ/USA.
2) https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/ Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results – Merck.com

 
About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates – including FYB208/dupilumab – are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com/

About Zydus Lifesciences Limited:
Zydus Lifesciences Limited is an innovation-led life-sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a global footprint across the United States, India and other international markets. As of September 30, 2025, the group employs 27,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:
Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 – 86 46 67 149

Fax: + 49 (0) 89 – 86 46 67 110

Sabrina.Mueller@formycon.com

 
Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

Not for release, publication or distribution, directly or indirectly, in or intothe United States of America, Australia, Canada or Japan or any otherjurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement need to be observed.

Berlin, December 9, 2025 – The Supervisory Board of Cantourage Group SE has appointed Mrs. Monique Jaqqam to the Management Board as Chief Financial Officer (CFO) with effect from January 1, 2026. In her new role, Mrs. Jaqqam will be responsible for finance, HR, legal, and IT. With her appointment, the Management Board of Cantourage Group SE expands to two members. Mrs. Jaqqam’s mandate is for five years.

In addition, the Supervisory Board has extended CEO Philip Schetter’s mandate for another five years, sending a clear signal of continuity and stability in corporate management.

“We are convinced that Mrs. Jaqqam’s proven financial expertise is an ideal addition to our Management Board team,” says Christian Schreyer, Chairman of the Supervisory Board of Cantourage Group SE. “Together with Mr. Philip Schetter (CEO), she will continue to drive the Group’s profitable growth.”

“I look forward to working with Monique Jaqqam. With her deep financial expertise, she strengthens our organization in precisely those areas that are essential for our further growth. Together, we will consistently shape the next phase of Cantourage’s development,” says Philip Schetter, CEO of Cantourage Group SE.

“In a dynamic growth environment, a resilient financial architecture is crucial. My goal is to consistently strengthen these structures and thus support the further growth of the Cantourage Group in a sustainable and transparent manner,” said Monique Jaqqam, commenting on her appointment as CFO.

About Monique Jaqqam

Monique Jaqqam holds a degree in business administration and has been Group CFO of the Future Group in Berlin since August 2023. She has more than 20 years of international management experience in finance, private equity, real estate, and hospitality. Previously, she was Group CFO at Basecamp Student and held senior finance positions at Kempinski Hotels. Her focus is on financial transformation, building modern financial structures, and supporting complex transactions.

About Cantourage
Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ISIN DE000A3DSV01

Further information: www.cantourage.com

Investor Relations contact at Cantourage
Manuel Taverne
taverne@cantourage.com

This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).